drugset
drugset / Trial / NCT06379165

Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain

NCT06379165 ↗

Phase 3 Completed 192 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of meloxicam nanocrystal injection in subjects with moderate to severe pain after abdominal surgery.

Timeline

Start
2023-05-17
Primary completion
2023-07-11
Completion
2023-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 30 mg Intravenous

Indications

No indication recorded.